🛡️ Public data only — no PHI permitted on this instance.
SC
SeekingChartis
Investment Committee Memorandum | TX | 23 beds | Grade C | EBITDA uplift $2.6M
Investment Committee Memorandum

ASCENSION SETON EDGAR B DAVIS

CCN 451371 | CALDWELL, TX | 23 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ASCENSION SETON EDGAR B DAVIS is a 23-bed suburban community hospital in CALDWELL, TX with $35.1M in net patient revenue and a 5.1% operating margin. The hospital serves a payer mix of 21.0% Medicare, 0.3% Medicaid, and 78.7% commercial.

Thesis: Turnaround. Our ML models identify $2.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.1% to 12.5% (+736bps).

Net Revenue HCRIS$35.1M
Current EBITDA COMPUTED$1.8M
Operating Margin COMPUTED5.1%
Occupancy HCRIS30.8%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS29.4%
Distress Probability ML50.5%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
235
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 5.1% places it above the state median. Among 235 size-comparable peers (12-46 beds), the median margin is -8.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-46), prioritizing same-state peers. 235 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ASCENSION SETON EDGAR B DAVIS (Target)TX23$35.1M5.1%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$738K+210bp18mo
Cost to Collect4.5%2.5%$703K+200bp12mo
Denial Rate Reduction12.0%6.5%$696K+198bp12mo
A/R Days Reduction5200.0%3800.0%$428K+122bp9mo
Clean Claim Rate88.0%96.0%$22K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$738K
Cost to Collect
$703K
Denial Rate Reduction
$696K
A/R Days Reduction
$428K
Clean Claim Rate
$22K
Total EBITDA Uplift$2.6M
Current EBITDA$1.8M
+ RCM Uplift+$2.6M
Pro Forma EBITDA$4.4M
Current Margin5.1%
Pro Forma Margin12.5%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.8M$37.8M13.58x68.5%
Base (11x exit)10.0x11.0x$2.8M$42.5M15.26x72.5%
Bull Case9.0x11.0x$2.5M$51.9M20.72x83.4%
Bull (12x exit)9.0x12.0x$2.5M$57.4M22.90x87.1%
Bear Case11.0x10.0x$3.1M$24.0M7.83x50.9%
Bear (11x exit)11.0x11.0x$3.1M$27.4M8.93x54.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 30.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 50.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 235 hospitals with 12-46 beds
  • Same-state prioritization (n=236)
  • Comp margins: P25=-37.9% / P50=-8.9% / P75=9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.

Full EBITDA BridgeML AnalysisHospital ProfileStatistical ProfileDeal Screener